Iatrogenic immunodeficiency-associated lymphoproliferative disorder in a child with B-cell acute lymphoblastic leukemia. (4th July 2019)

• Record Type: Journal Article
• Authors: Shahid, Sanam; Rossi, Christopher; Vyas, Pranav; Bollard, Catherine; Dave, Hema
• Is Part Of: Pediatric hematology and oncology. Volume 36:Number 5(2019)
• Page Start: 309
• Page End: 316
• Publication Date: 2019-07-04
• Subjects: Iatrogenic immunodeficiency-associated lymphoproliferative disorder -- nasopharyngeal EBV-positive B-cell lymphoproliferative disorder -- polymorphic post-transplant lymphoproliferative disorder -- rituximab; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Hematologic Diseases -- Child; Hematologic Diseases -- Infant; Neoplasms -- Child; 618.9215
• DOI: 10.1080/08880018.2019.1637982
• Languages: English
• ISSNs: 0888-0018

Abstract

Abstract: Iatrogenic immunodeficiency-associated lymphoproliferative disorders (LPDs) are a group of lymphoid proliferations or lymphomas that are well known to be associated with an immunosuppressed state. These disorders most commonly occur following hematopoietic or solid organ transplantation (called post-transplant lymphoproliferative disorders or PTLD), but cases have also been described during the treatment of autoimmune and rheumatologic disorders by immunosuppressive and immunomodulatory medications. These disorders are strongly associated with infection by the Epstein-Barr virus (EBV) as a result of impaired immune function in the immunosuppressed state. While this phenomenon has been well documented in autoimmune conditions, cases affecting pediatric patients while on anti-leukemia chemotherapy are lacking. In this report, we describe a case of a pediatric immunosuppressed patient with recurrent sinusitis found to have a nasopharyngeal mass consistent with EBV-positive B-cell lymphoproliferative disorder resembling a polymorphic PTLD during the maintenance phase of B-cell Acute Lymphoblastic Leukemia (ALL) therapy. The patient was successfully treated with rituximab without any cytotoxic chemotherapy, highlighting the importance of recognizing this clinical entity in non-transplant patients with hematologic malignancies.